The United States Patent and Trademark Office (USPTO) has published a patent application, US20260085059A1, detailing therapeutic compounds and their methods of use for treating cancer. The application, filed by Servier Pharmaceuticals LLC, includes specific compound classifications (CPC: C07D 401/14, A61K 9/2054, A61K 9/2059, A61K 31/444, A61K 31/53, A61P 35/00, C07B 2200/13) and lists Samuel V. Agresta, Chong-Hui Gu, David Schenkein, Hua Yang, Liting Guo, Zhen Tang, Jianming Wang, Yanfeng Zhang, and Yan Zhou as inventors. The application was filed on May 7, 2025, and published on March 26, 2026.

This publication represents a new intellectual property filing for potential cancer treatments. While not a regulatory rule, it signifies a step in the drug development process for Servier Pharmaceuticals LLC. Companies operating in the pharmaceutical sector, particularly those involved in oncology research and development, should note this patent filing as it pertains to novel therapeutic compounds. No immediate compliance actions are required for other entities, but it may influence future competitive landscapes or licensing opportunities.